SCHEMBL3715844

SCHEMBL3715844

CC(=O)C1=C(O)C(=O)N(CCc2ccccc2)C1c1ccc(Br)cc1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.61
ALOX15 P16050 2/20 0.61
LMNA P02545 1/20 0.61
ALDH1A1 P00352 6/20 0.59
SMN1; SMN2 Q16637 1/20 0.55
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
USP7 Q93009 1/20 0.53
CCR1 P32246 1/20 0.52
CCR2 P41597 1/20 0.52
HPGD P15428 3/20 0.51
HTT P42858 1/20 0.51
GAA P10253 2/20 0.50
TSHR P16473 1/20 0.50
TP53 P04637 1/20 0.50
MDM2 Q00987 1/20 0.50
KDM4E B2RXH2 3/20 0.48
HIF1A Q16665 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
RXFP1 Q9HBX9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3705340 0.82 MEN1 (0.78) POLBALOX15LMNAALDH1A1MEN1
SCHEMBL3714413 0.79 USP7 (0.73) POLBALOX15LMNAALDH1A1SMN1; SMN2
SCHEMBL3704381 0.77 MEN1 (0.70) POLBALOX15LMNAALDH1A1SMN1; SMN2
SCHEMBL3706706 0.77 MEN1 (0.60) POLBALOX15LMNAALDH1A1SMN1; SMN2
SCHEMBL3713655 0.77 USP7 (0.60) POLBALOX15LMNAALDH1A1MEN1
SCHEMBL3714403 0.76 USP7 (0.69) POLBALOX15LMNAALDH1A1SMN1; SMN2
SCHEMBL3705385 0.76 USP7 (0.79) ALOX15LMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL3709204 0.76 MEN1 (0.74) ALOX15LMNAALDH1A1MEN1KMT2A
SCHEMBL3707749 0.76 USP7 (0.71) ALOX15LMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL3705034 0.75 USP7 (0.59) POLBALOX15LMNAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP claimed
US-20220125760-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) 2022-04-28 US disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed